This technology is a protocol for efficiently culturing cancer cells obtained from bladder biopsies for rapid evaluation of chemotherapeutic response.
While stable bladder cancer cell lines are commercially available for drug development and testing, they are unable to predict an individual’s response to chemotherapy. Existing methods to culture patient-derived bladder cancer cells typically require a large amount of biopsy tissue and suffer from short survival times and poor production efficacy, which limits their use in precision medicine. As such, an efficient method to culture patient-specific bladder cancer cells could enable patient-specific drug testing for personalized treatment plans.
This technology provides a culture method that only requires a small tissue sample to grow patient-specific bladder cancer cells with high efficiency and extended survival time. The ability to easily establish patient-specific cancer cell lines enables in vitro assessment of therapeutic response, allowing physicians to establish individualized treatment plans. Moreover, these cancer cell lines can be frozen for long-term storage, which could contribute to studying the pathophysiology and future treatments for bladder cancer.
This technology has been validated with human bladder tumor specimens.
Patent Pending (US 20170152486)
IR CU14280
Licensing Contact: Joan Martinez